Table 6. In vivo histone protein... | American Society of Hematology

Table 6.

In vivo histone protein acetylation in CLL patient cells following depsipeptide treatment

	Relative increase in H4 acetylation, % before treatment			Relative increase in H3 acetylation, % before treatment			Relative HDAC enzyme activity, % before treatment	Maximum reduction in lymphocyte count, %
Patient no.	4 h after treatment	24 h after treatment	4 h after treatment	24 h after treatment	4 h after treatment	24 h after treatment		Maximum reduction in lymphocyte count, %
1	260	170	240	800	26.0	52.5	45
2	630	440	460	370	19.4	64.1	76
3	200	230	240	410	30.6	45.3	61
4	390	770	510	330	16.2	86.8	59
5	800	270	440	260	24.2	58.3	50
6	340	240	260	100	37.5	66.2	50
7	300	200	630	390	36.2	80.2	62

	Relative increase in H4 acetylation, % before treatment			Relative increase in H3 acetylation, % before treatment			Relative HDAC enzyme activity, % before treatment	Maximum reduction in lymphocyte count, %
Patient no.	4 h after treatment	24 h after treatment	4 h after treatment	24 h after treatment	4 h after treatment	24 h after treatment		Maximum reduction in lymphocyte count, %
1	260	170	240	800	26.0	52.5	45
2	630	440	460	370	19.4	64.1	76
3	200	230	240	410	30.6	45.3	61
4	390	770	510	330	16.2	86.8	59
5	800	270	440	260	24.2	58.3	50
6	340	240	260	100	37.5	66.2	50
7	300	200	630	390	36.2	80.2	62

Data are shown as percentage relative to the pretreatment sample in each case, set at 100%. Increases of H3 and H4 acetylation of at least 100% more than the pretreatment sample (ie, 200% before treatment or greater) are considered to meet the MEPD criteria.

View Large

This Feature Is Available To Subscribers Only